DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
DYADIC INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.03 (-7.35%)
Close on Oct 19, 2026
- Market cap
- $13.88M
- P/E (TTM)
- –
- Dividend yield
- –
DYADIC INTERNATIONAL INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant [Member] | $837.25K | $487.37K | $329.81K | $814.57K | $503.18K | $210.47K | – | – | – | $0 | – | – | 87.1% | +66.4% |
| Research And Development Expenses [Member] | $123.89K | $403.59K | – | – | $213.45K | $183.10K | – | – | – | – | – | – | 12.9% | -42.0% |
| License [Member] | $0 | $220.00K | $15.00K | $0 | $250.00K | – | $465.17K | $1.43M | $0 | $0 | $220.59K | $44.12K | 0.0% | -100.0% |
| Research And Development [Member] | – | – | $220.72K | $350.05K | $213.45K | $183.10K | $352.21K | $532.50K | $385.90K | $334.62K | $465.95K | $352.94K | – | – |
By region
From the segment and revenue-disaggregation notes of Dyadic International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.